La cadena de opciones muestra datos clave de las opciones de acciones de M3-Brigade Acquisition a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para M3-Brigade Acquisition..

M3-Brigade Acquisition (NASDAQ:MBAV) Bolsa, Cadena de Opciones

M3-Brigade Acquisition V Corp is a blank check company.

M3-Brigade Acquisition V Corp. - Class A Ordinary shares

M3-Brigade Acquisition V Corp

Cantor Fitzgerald analyst Sarah James maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $168 to $177.

News

Price Target

Analyst Ratings

Cantor Fitzgerald Maintains Overweight on Tenet Healthcare, Raises Price Target to $177

Morgan Stanley analyst Toni Kaplan maintains MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Overweight and raises the price target from $640 to $662.

MSCI

Morgan Stanley Maintains Overweight on MSCI, Raises Price Target to $662

Flex Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) shares are trading higher after the company reported better-than-expected second-quarter financial results and raised its full-year earnings guidance.
The company reported adjusted earnings per share 64 cents, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41622640/flex-reports-second-quarter-fiscal-2025-results" rel="noreferrer noopener">analyst consensus estimate of 56 cents</a>. Quarterly sales of $6.545 billion beat the street view of $6.532 billion.
The company registered a second-quarter gross profit of $531 million, higher than the $519 million reported in the year-ago period.
Flex exited the quarter with cash and equivalents worth $2.601 billion. Inventories at quarter end totaled $5.466 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" rel="noreferrer noopener">DJT Short Squeeze Could Push Stock To $60 If Trump Wins, But Analysis Says Loss Could Make Shares &#8216;Worthless&#8217;</a>
Outlook: Flex expects its third-quarter revenues to be between $6.0 billion and $6.4 billion, slightly below the analyst estimate of $6.54 billion.
Additionally, the company anticipates adjusted earnings per share in the range of $0.60 &#8211; $0.66 versus the consensus estimate of $0.65.
Flex has revised its fiscal year 2025 revenue outlook to a range of $24.9 billion &#8211; $25.5 billion, down from the previous estimate of $25.4 billion &#8211; $26.4 billion, and <a href="https://www.benzinga.com/calendars/guidance">below the analyst estimate of $25.78 billion. </a>
Additionally, the company revised its adjusted earnings per share guidance to between $2.39 and $2.51, up from $2.30 &#8211; $2.50 and compared to the consensus estimate of $2.41.
Price Action: FLEX shares are trading higher by 3.17% to $35.77 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/10/41603930/trump-vs-musk-djt-stock-worth-more-than-latest-x-valuation-thanks-to-2024-election-run-up" target="_blank" rel="noreferrer noopener">Trump Vs. Musk: DJT Stock Worth More Than Latest X Valuation Thanks To 2024 Election Run-Up</a></li>
</ul>

Earnings

Equities

Markets

Movers

General

FLEX

Flex Ltd. Surpasses Q2 Expectations And Lifts FY25 EPS Guidance: Details

Morgan Stanley analyst Vikram Purohit maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Equal-Weight and raises the price target from $64 to $69.

INCY

Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $69

WIIM

Trump Media & Technology shares are trading lower. The stock has been highly volatile ahead of the of the upcoming US presidential election.

Morgan Stanley analyst Chris Snyder maintains Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) with a Equal-Weight and raises the price target from $407 to $445.

HUBB

Morgan Stanley Maintains Equal-Weight on Hubbell, Raises Price Target to $445

Cantor Fitzgerald analyst Charles Duncan maintains Harmony Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Overweight and raises the price target from $51 to $58.

HRMY

Cantor Fitzgerald Maintains Overweight on Harmony Biosciences, Raises Price Target to $58

Canaccord Genuity analyst Kyle Rose maintains Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and raises the price target from $360 to $400.

Canaccord Genuity Maintains Buy on Stryker, Raises Price Target to $400

AMAT

ASML

AVGO

INTC

KLAC

LRCX

LSCC

MCHP

MRVL

NVDA

NXPI

QCOM

RMBS

SIMO

TSEM

Shares of chip stocks are trading lower. The sector may be under pressure after AMD and Qorvo fell on their respective earnings reports and outlook. Additionally, SMCI may be causing sector uncertainty after its independent auditor resigned.

Morgan Stanley analyst Ricky Goldwasser maintains Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Underweight and raises the price target from $26 to $33.

DOCS

Morgan Stanley Maintains Underweight on Doximity, Raises Price Target to $33

Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) has outperformed the market over the past 20 years by 1.74% on an annualized basis producing an average annual return of 10.08%. Currently, Crown Castle has a market capitalization of $46.48 billion. 
Buying $100 In CCI: If an investor had bought $100 of CCI stock 20 years ago, it would be worth $682.09 today based on a price of $106.95 for CCI at the time of writing.
<h3>Crown Castle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730309427_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Crown Castle 20 Years Ago Would Be Worth Today

Canaccord Genuity analyst Maria Ripps maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Hold and raises the price target from $12 to $13.

SNAP

Canaccord Genuity Maintains Hold on Snap, Raises Price Target to $13

RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) has outperformed the market over the past 15 years by 7.01% on an annualized basis producing an average annual return of 18.98%. Currently, RBC Bearings has a market capitalization of $8.31 billion. 
Buying $1000 In RBC: If an investor had bought $1000 of RBC stock 15 years ago, it would be worth $14,181.19 today based on a price of $285.83 for RBC at the time of writing.
<h3>RBC Bearings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730309421_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today

Morgan Stanley analyst Michael Phillips maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Equal-Weight and raises the price target from $295 to $300.

Morgan Stanley Maintains Equal-Weight on Chubb, Raises Price Target to $300

Canaccord Genuity analyst Joseph Vafi maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Buy and raises the price target from $80 to $96.

PYPL

Canaccord Genuity Maintains Buy on PayPal Holdings, Raises Price Target to $96

Morgan Stanley analyst Richard Hill maintains American Assets Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAT#NYSE">AAT</a>) with a Equal-Weight and raises the price target from $23 to $24.

Morgan Stanley Maintains Equal-Weight on American Assets Trust, Raises Price Target to $24

Cantor Fitzgerald analyst Brett Knoblauch reiterates Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Overweight and maintains $20 price target.

Reiteration

IREN

Cantor Fitzgerald Reiterates Overweight on Iris Energy, Maintains $20 Price Target

On-chain analytics provider Solonchain highlighted a whale who made more than $2.5 million trading several meme coins, <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41547554/trader-nets-157-000-from-viral-baby-hippo-moodeng-and-ai-meme-coin-sensation-goat">such as Goatseus Maximus (GOAT)</a>.
What Happened: The whale&#8217;s recent successful trades include accumulating LUCE, GOAT and FWOG, making significant profits of 533%, 1788% and 1,200%, respectively. 
Solonchain <a href="https://x.com/CryptobigM/status/1851249828111495170">highlighted</a> the trader&#8217;s knack for identifying meme coins with the potential to reach over $200 million market capitalization and buying in early. The trader has demonstrated effective risk management, with few significant losses over the past 90 days.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41552276/the-hottest-sectors-in-crypto-ai-memes-and-one-surprise-says-veteran-analyst">The Hottest Sectors In Crypto? AI, Memes And One Surprise, Says Veteran Analyst</a>
Why It Matters: The success of this whale underscores the potential profitability of memecoins, despite their inherent volatility and risk. Solonchain&#8217;s tweet suggests that careful selection and risk management can yield substantial returns in this niche market.
According to pseudonymous trader Altcoin Sherpa, GOAT is <a href="https://x.com/AltcoinSherpa/status/1851616058005672379">likely</a> to see a pullback to around $0.47 (the 0.50 Fibonacci level), indicating a possible breather for on-chain assets after their rally. Attention may turn toward centralized exchange coins, according to the trader.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41606090/bitcoin-meme-coins-thats-right-trader-says-best-time-to-get-in-as-dogecoin-solana-memes-su">Bitcoin Meme Coins? That&#8217;s Right, Trader Says &#8216;Best Time To Get In&#8217; As Dogecoin, Solana Memes Surge</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$2.5 Million From Meme Coins? One Trader Seems To Have Cracked The Code

Raymond James analyst Craig Stanley maintains Rio2 (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/RIO#TSXV">RIO</a>) with a Outperform and raises the price target from C$0.9 to C$1.15.

TSXV:RIO

Raymond James Maintains Outperform on Rio2, Raises Price Target to C$1.15

Canaccord Genuity analyst William Plovanic maintains CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) with a Buy and raises the price target from $15 to $17.

CVRX

Canaccord Genuity Maintains Buy on CVRx, Raises Price Target to $17

Shares of OS Therapies fell on Thursday following a downsized initial public offering by the oncology drug developer in a slow week for the IPO market.

Comments

M3-Brigade Acquisition

M3-Brigade Acquisition (MBAV) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL